“Mechanistic Insights into MCR-1/2 Colistin Resistance”

Dr. Youjun Feng
School of Medicine/College of Animal Sciences
Zhejiang University, Hangzhou, China

Date: 21 December 2017
Time: 11:00am to 12:30pm
Venue: Meeting Room 2-130, 1/F, Block 2, To Yuen Building

Abstract
Antibiotic resistance is becoming a prevalent threat to the provision of safe and effective health care worldwide. Antimicrobial resistance (AMR) is associated with 700,000 deaths each year. It is estimated by O’Neill and his team that AMR would claim for as many as 10,000,000 global deaths per year by 2050. Despite that this prediction is exaggerated and unreliable, we acknowledge that AMR has been posing an ever-growing burden on clinical therapies and public health, thereby highlighting the urgent need for nationwide response to alleviate this burden. Polymyxins, a class of cationic cyclic polypeptide antibiotics, act as a “last-resort” option against infections with carbapenem-resistant gram-negative pathogens. However, the emergence and global spread of plasmid-borne mobilized colistin resistance determinants (mcr-1) has greatly threatened the renewed interest of colistin (polymyxin E) in clinical therapies. To the best of our knowledge, mcr-1-harboring Enterobacteriaceae have been detected in no less than 40 countries worldwide, spanning 5 of 7 continents, of which the United States of America is not exceptional. This talk concentrates on research work in Dr. Feng’s lab in the past two years, esp., mechanistic insights into MCR-1/2 colistin resistance: i) genetic and functional identification of transferable MCR-1/2 resistance to polymyxin, a last line of refuge against lethal infections by superbugs with carbapenem resistance; ii) complex dissemination and spread of diversified plasmids-aided mcr-1 determinants amongst human/animal gut microbiota. Our long-term research plan is aiming to provide molecular basis for the rational development of small molecules targeting the reversal of MCR-like resistance to colistin, a last-resort antibiotic against multi-drug resistant pathogens.

About the Speaker
Dr. Feng, a recipient of the “Young 1000 Talents” award, is a professor in School of Medicine/College of Animal Sciences, Zhejiang University. Dr. Feng’s research interest focuses on metabolism, pathogenesis and antibiotic resistance of gut microbiota. So far, Dr. Feng has been authored in more than 90 peer-reviewed international journals including PLoS Pathogens, mBio, Microbiome, etc. Also, Dr. Feng is an editorial board member of Journals Virulence, Frontiers in Cellular and Infection Microbiology (FCIM) and Scientific Reports.

Enquiry:
Dr Xin Deng (3442-5693, xindeng@cityu.edu.hk)
Ms Irene Wong (3442-4707, irene.wong@cityu.edu.hk)

All are welcome!